While overall orthopedic M&A activity slowed in the wake of the pandemic, some companies remain highly acquisitive. This month’s chart shows the ten most acquisitive orthopedic companies since 2020. These companies combined for 38 transactions over the last two and half years, accounting for more than a third of all acquisitions over that span.
What are these active companies buying? Looking deeper at these 38 transactions, we see that 30% were related to the foot and ankle segment while enabling technology deals accounted for 23%.
Enovis comfortably leads the pack with eight acquisitions since 2020. The company rapidly built a foot and ankle business through tuck-in deals while securing significant international expansion through its Mathys purchase.
“There was this myth that most acquisitions fail,” said Enovis CEO Matt Trerotola. “Then a famous paper came out that said, yeah, most acquisitions fail unless you’re a company that does them regularly. That’s us. We do M&A on a regular basis. We’ve got discipline and a toolkit; it’s all rooted in strategy. We do them because they accelerate our strategy, open a new market or bring in a key technology.”
While overall orthopedic M&A activity slowed in the wake of the pandemic, some companies remain highly acquisitive. This month's chart shows the ten most acquisitive orthopedic companies since 2020. These companies combined for 38 transactions over the last two and half years, accounting for more than a third of all acquisitions over that...
While overall orthopedic M&A activity slowed in the wake of the pandemic, some companies remain highly acquisitive. This month’s chart shows the ten most acquisitive orthopedic companies since 2020. These companies combined for 38 transactions over the last two and half years, accounting for more than a third of all acquisitions over that span.
What are these active companies buying? Looking deeper at these 38 transactions, we see that 30% were related to the foot and ankle segment while enabling technology deals accounted for 23%.
Enovis comfortably leads the pack with eight acquisitions since 2020. The company rapidly built a foot and ankle business through tuck-in deals while securing significant international expansion through its Mathys purchase.
“There was this myth that most acquisitions fail,” said Enovis CEO Matt Trerotola. “Then a famous paper came out that said, yeah, most acquisitions fail unless you’re a company that does them regularly. That’s us. We do M&A on a regular basis. We’ve got discipline and a toolkit; it’s all rooted in strategy. We do them because they accelerate our strategy, open a new market or bring in a key technology.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
